A study published in JACC: Advances has shown that a risk prediction algorithm incorporating HeartBeam Inc.'s (NASDAQ: BEAT) portable ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an area under the curve (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. This increased to 92.9% when a personal, symptom-free baseline ECG was available for comparison.
HeartBeam, a medical technology company focused on transforming cardiac care, announced the results as supporting heart attack detection as a future indication for the HeartBeam System. The company said the findings advance its broader clinical program. The HeartBeam device is a cable-free, credit card-sized tool that can collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG.
The study's results are significant because they demonstrate the potential for portable, at-home ECG monitoring to help identify patients at high risk of heart attack, potentially enabling earlier intervention. The algorithm's high AUC values suggest strong predictive accuracy, which could reduce unnecessary hospital visits and improve patient outcomes.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology. For more details on the intended use of its technology, refer to the company's cleared indications for use.
The full press release is available at https://ibn.fm/ainxV. For the latest news and updates on HeartBeam, visit the company's newsroom at https://ibn.fm/BEAT.
